FDA approvals for pediatric cancer indications using children’s oncology group associated trials data

Key Points

• The aim is to evaluate the role of COG trials in supporting FDA approvals for pediatric oncology drugs.
• Reviewed FDA approval data for pediatric oncology therapeutics
• Analyzed COG trial contributions to these approvals
• Evaluated the public-private partnership effectiveness
• Nearly 50% of FDA approved pediatric cancer drugs relied on COG trial data
• Highlights the importance of COG trials in regulatory decision-making
• Reinforces the partnership model for drug development in pediatrics

Abstract